Keith Tapper
Stock Analyst at BMO Capital
(2.55)
# 2,134
Out of 5,169 analysts
6
Total ratings
66.67%
Success rate
16.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $45 → $16 | $19.50 | -17.95% | 4 | Apr 14, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $4.45 | +12.36% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $20.32 | +52.56% | 1 | Jun 27, 2024 |
Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45 → $16
Current: $19.50
Upside: -17.95%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $4.45
Upside: +12.36%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $20.32
Upside: +52.56%